Now let me run a set of searches covering recent selegiline research from several angles.

The full results were saved to a file. Let me extract the relevant entries.

Strong set of leads. Let me open the most important primary sources and run a couple of supplementary searches in parallel.

Several key pages were blocked. Let me try alternate mirrors and sources for the core papers.

Good progress. Let me fill remaining gaps: the rasagiline-vs-selegiline meta-analysis, the Frontiers Pharmacology aging paper, the PDI mechanism paper, and the pediatric study, plus a sweep for the very latest papers.

I now have a rich picture. Let me pull details from three remaining papers and load the canvas skill in parallel, since I'll deliver the report as a canvas.

All research gathered. Now I'll write up the findings as a research-brief canvas.

Done — I've compiled the research into a canvas report: "Selegiline: The Latest Research (2025–2026)".

Top takeaways:

• Longevity: A 2025 meta-analysis of 22 rodent lifespan experiments (Ageing Research Reviews) found L-deprenyl reliably extends lifespan (SMD 0.68, p = 0.0002), with larger effects at higher doses and later start ages — though a dog-study re-analysis lost significance and no human trial exists ( ScienceDirect,  Rapamycin News).
• New mechanism: Selegiline directly blocks the pro-apoptotic activity of protein disulfide isomerase — an MAO-independent neuroprotective action discovered via click-chemistry profiling ( Molecular Biomedicine).
• Psychiatry: A real-world study of 117 treatment-resistant depression patients found the selegiline patch beat tricyclics, was the best-tolerated MAOI option, and produced no hypertensive crises or serotonin syndrome ( J Affect Disord,  Carlat Report).
• Parkinson's: A randomized Japanese trial (DATSZ-PD) saw dopamine-terminal decline roughly halved on DAT-SPECT with selegiline added to levodopa — suggestive of disease modification but not conclusive (p = 0.079) ( MDS Abstracts).

The canvas includes the full findings (including oncology repurposing, cognition/QoL comparisons with rasagiline, formulation science), a rated source table, open questions, and next steps. Given your second-edition work on Can Biotechnology Abolish Suffering?, I flagged the three most quotable additions for the deprenyl-related passages in the recommendations section (No access).